3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Observational
4
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Sarcoma
1
Rare Diseases
1
Neuroblastoma
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Genetic Predisposition to Disease
1
Breast Neoplasms
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
92
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
52
Doxorubicin
50
trametinib
47
atezolizumab
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
High-Throughput Nucleotide Sequencing
×
Clear all
NCT02780128
2026-03-10
NEPENTHE
Children's Hospital of Philadelphia
Phase 1
Terminated
66 enrolled